NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma
Phase 1 other active
Quick answer
NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma for resectable esophagogastric adenocarcinoma is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- resectable esophagogastric adenocarcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active